Carbamazepine (All indications) updated on 04-22-2025

Eye, ear, face and neck malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17486
R73495		 Wiggs (Epilepsy) (Carbamazepine), 2024 Eye, ear, face and neck malformations early pregnancy population based cohort retrospective unexposed, sick Adjustment: Yes 0.55 [0.21;1.45] -/1,456   -/12,666 - 1,456
ref
S9643
R34316		 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Eye, ear, face, neck throughout pregnancy population based cohort retrospective exposed to other treatment, sick Adjustment: No 0.40 [0.02;9.96] C 0/685   1/833 1 685
ref
Total 2 studies 0.54 [0.21;1.35] 1 2,141
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wiggs (Epilepsy) (Carbamazepine), 2024Wiggs, 2024 1 0.55[0.21; 1.45]-1,45692%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014Veiby, 2014 2 0.40[0.02; 9.96]16858%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.54[0.21; 1.35]12,1410.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy) (Carbamazepine; 2: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.54[0.21; 1.35]12,1410%NAWiggs (Epilepsy) (Carbamazepine), 2024 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.55[0.21; 1.45]-1,456 -NAWiggs (Epilepsy) (Carbamazepine), 2024 1 exposed to other treatment, sickexposed to other treatment, sick 0.40[0.02; 9.96]1685 -NAVeiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 0.40[0.02; 9.96]1685 -NAVeiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 1   - Yes  - Yes 0.55[0.21; 1.45]-1,456 -NAWiggs (Epilepsy) (Carbamazepine), 2024 1 All studiesAll studies 0.54[0.21; 1.35]12,1410%NAWiggs (Epilepsy) (Carbamazepine), 2024 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.55[0.21; 1.45]-1,456 -NAWiggs (Epilepsy) (Carbamazepine), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.40[0.02; 9.96]1685 -NAVeiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 10.510.01.0